

## Thalidomide-O-C4-COOH Biochemical

Thalidomide-O-C4-COOH

CATALOG #  
**AAA228183**


### PRODUCT SYNONYMS

Thalidomide-O-C4-COOH; Thalidomide-O-C4-COOH biochemical


### PRODUCT SPECIFICATIONS

|                         |                                                                                                                                                                                                                                                           |
|-------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Purity/Purification     | 98%                                                                                                                                                                                                                                                       |
| CAS                     | 2169266-67-3                                                                                                                                                                                                                                              |
| Solubility              | <1mg/ml refers to the product slightly soluble or insoluble                                                                                                                                                                                               |
| In vitro                | PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[2]. |
| Preparation and Storage | Powder: -20 degree C for 3 years<br>In solvent: -80 degree C for 2 years                                                                                                                                                                                  |

### IMAGES



Structure  
Palmitic acid-13C16 sodium, CAS 2483736-17-8



Structure  
Palmitic acid-13C16 sodium, CAS 2483736-17-8

### ADDITIONAL INFORMATION

|                                                                   |                                                                                                                                                                                                                                                                                                                                                                 |
|-------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Related Product Information for Thalidomide-O-C4-COOH biochemical | Thalidomide-O-C4-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.                                                                                                                                                                                        |
| References                                                        | <ol style="list-style-type: none"> <li>Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.</li> <li>Harada H, et al. Antitumor activity of palmitic acid found as a selective cytotoxic substance in a marine red alga. Anticancer Res. 2002 Sep-Oct;22(5):2587-90.</li> </ol> |

**For Research Use Only.** Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

